MedTrace Logo

NIOSH R21 WTC Asthma

NCT07222501 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2026-03-27

No results posted yet for this study

Summary

Aim 2: Conduct a pilot RCT of SaMBA-WTC to determine feasibility and preliminary impact in preparation for a fully powered trial. (7M-24M) The investigators will conduct a pilot RCT (n=58) of the SaMBA-WTC model vs. an attention control. Data will be collected on the primary outcomes (asthma control \[asthma control test, ACT\], medication use, inhaler technique) as well as on other secondary outcomes including measures of physical function, self-management behaviors, feasibility and fidelity at baseline, at intervention completion at 3 months, and for sustainability at 6 months. This project will prepare the team for all aspects of a subsequent larger efficacy trial of SaMBA-WTC.

Conditions

Interventions

BEHAVIORAL

SaMBA

The health coach will ask many questions to determine how best to help asthma management and to improve asthma control. The intervention lasts 3 months. During those 3 months, the health coach will speak with participant by phone or video chat several times. Meetings will occur once a week for the first 2-3 weeks, then every 2-4 weeks until the intervention ends. The days and times of the meetings will be up to the participant.

BEHAVIORAL

Asthma Education - WTC Related

1-3 visits with an asthma educator to receive basic asthma education

Sponsors & Collaborators

Principal Investigators

  • Juan Wisnivesky, MD, DrPH · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2026-07-01
Completion
2026-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07222501 on ClinicalTrials.gov